A Case Whose Delirium Improved with Discontinuation of Continuous Deep Sedation Initiated for Refractory Delirium at the End Stage of Cancer

<p>Introduction: We herein report a case whose terminal refractory delirium improved after discontinuation of continuous deep sedation for several days. Case: A 57-year-old head and neck cancer woman with brain parenchymal invasion was consulted to our palliative care team for delirium accompanied by sudden abnormal behavior. Her abnormal behavior did not improve with opioid switching or drug treatment. She was diagnosed as refractory end of life delirium, and her family wanted her to be sedated. We started intermittent sedation with midazolam and then shifted to continuous deep sedation. Several days later, her family expressed the conflict of continuing sedation. Ten days later we stopped sedating her according to her family’s will. She awoke from deep sedation and her abnormal behavior disappeared, although there was mild consciousness disturbance. The patient died 2 months later while maintaining communication with her family. Discussion: Cessation of various drugs which may provoke delirium is considered to be one of the causes of delirium improvement in this case. The guidelines of the Japanese Society of Palliative Medicine do not clearly state the criteria for suspension of deep sedation other than confirming the feelings of family members. A criterion for withdrawal of sedation should be discussed based on higher evidence level.</p>

Continuous Deep Sedation to Terminally Ill Cancer Patients in the General Ward Who Were Referred to Palliative Care Team: A Retrospective Analysis

<p>Although continuous deep sedation (CDS) is sometimes used for terminally ill cancer patients to alleviate intolerable symptoms, there are few studies that comprehensively investigated CDS in general ward, including the rate of discussions by multiple occupations. The aim of this study was to retrospectively investigate the present state of CDS for patients in the general ward who were referred to the palliative care team (PCT). A total of 938 terminal cancer patients who were consulted with PCT between August 2012 and October 2015 were enrolled. Of the 938 patients enrolled in the study, 246 patients died in the general ward before the end of November 2015. Of the 246 patients, 28 patients (11.4%) were treated with CDS to alleviate intolerable symptoms in the terminal period. The mean duration of CDS was 4.1±3.1 days. Lung cancer was the most common in primary disease. The primary reason for starting CDS was dyspnea. All CDS were performed with midazolam. The discussions on CDS by multiple occupations were performed in all cases. We conclude that on weekdays the PCT visited the patient every day and was able to sedate all cases with sedation discussion by multiple occupations.</p>